Literature DB >> 18326554

Vasoconstrictor effect of aldosterone via angiotensin II type 1 (AT1) receptor: possible role of AT1 receptor dimerization.

Masahiro Yamada1, Motoi Kushibiki, Tomohiro Osanai, Hirofumi Tomita, Ken Okumura.   

Abstract

AIMS: We recently demonstrated that aldosterone induces a non-genomic vasoconstrictor effect on rat coronary arterioles and that this effect was blocked by angiotensin II type 1 receptor (AT1) blockers. Intracellular transglutaminase enhances AT1 signalling by cross-linking AT1 homodimers. The purpose of this study was to confirm the AT1-dependency of the vasoconstrictor effect of aldosterone using AT1a knockout (AT1aKO) mice and to investigate the role of intracellular transglutaminase and AT1 dimerization in this effect. METHODS AND
RESULTS: The mesenteric arterioles (60-160 microm) were isolated from C57BL/6J (wild-type, WT) and AT1aKO mice, and the internal diameter was measured by video microscopy. Aldosterone (10(-13) to 10(-6) M), but not hydrocortisone, produced a dose-dependent vasoconstriction in WT mice; the maximal diameter change was -8.6 +/- 0.3% from the baseline (P < 0.001). This vasoconstrictor effect was unaffected by the mineralocorticoid receptor antagonist spironolactone or eplerenone, the AT2 antagonist PD123319, the glucocorticoid receptor antagonist RU486, or endothelium denudation. Aldosterone's vasoconstrictor effect was negligible in AT1aKO mice. The AT1 blockers valsartan or candesartan suppressed aldosterone-induced vasoconstriction in WT mice. The transglutaminase inhibitors cystamine and monodansyl cadaverine also suppressed the vasoconstrictor effect of aldosterone, without affecting the vasoconstrictor effect of angiotensin II in WT mice. AT1 dimer protein levels were increased in WT mesenteric arterioles treated with 10(-7) M aldosterone, and the transglutaminase inhibitor and AT1 blocker blocked this aldosterone-induced formation of AT1 dimer. Treatment with 10(-7) M aldosterone for 10 min increased the transglutaminase activity by 2.5 +/- 0.2-fold in cultured vascular smooth muscle cells and by 1.2 +/- 0.1-fold in the mesenteric arterioles. These increases were abolished by transglutaminase inhibitors.
CONCLUSION: Aldosterone produces a non-genomic, endothelium-independent vasoconstrictor effect by enhancing intracellular transglutaminase activity and presumably inducing AT1 dimer formation in mesenteric arterioles.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18326554     DOI: 10.1093/cvr/cvn064

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  14 in total

Review 1.  International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli [corrected].

Authors:  Sadashiva S Karnik; Hamiyet Unal; Jacqueline R Kemp; Kalyan C Tirupula; Satoru Eguchi; Patrick M L Vanderheyden; Walter G Thomas
Journal:  Pharmacol Rev       Date:  2015-10       Impact factor: 25.468

Review 2.  Aldosterone blockade in chronic kidney disease: can it improve outcome?

Authors:  Robert D Toto
Journal:  Curr Opin Nephrol Hypertens       Date:  2010-09       Impact factor: 2.894

Review 3.  Heart of the matter: coronary dysfunction in metabolic syndrome.

Authors:  Zachary C Berwick; Gregory M Dick; Johnathan D Tune
Journal:  J Mol Cell Cardiol       Date:  2011-07-13       Impact factor: 5.000

4.  Aldosterone-induced brain MAPK signaling and sympathetic excitation are angiotensin II type-1 receptor dependent.

Authors:  Zhi-Hua Zhang; Yang Yu; Shun-Guang Wei; Robert B Felder
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-11-11       Impact factor: 4.733

Review 5.  Role of mineralocorticoid receptor antagonists in cardiovascular disease.

Authors:  Carlos M Ferrario; Ernesto L Schiffrin
Journal:  Circ Res       Date:  2015-01-02       Impact factor: 17.367

Review 6.  Pathophysiology and treatment of resistant hypertension: the role of aldosterone and amiloride-sensitive sodium channels.

Authors:  Eric K Judd; David A Calhoun; David G Warnock
Journal:  Semin Nephrol       Date:  2014       Impact factor: 5.299

Review 7.  Genomic and rapid effects of aldosterone: what we know and do not know thus far.

Authors:  Milla Marques Hermidorff; Leonardo Vinícius Monteiro de Assis; Mauro César Isoldi
Journal:  Heart Fail Rev       Date:  2017-01       Impact factor: 4.214

Review 8.  Aldosterone and cardiovascular disease: the heart of the matter.

Authors:  B Julie He; Mark E Anderson
Journal:  Trends Endocrinol Metab       Date:  2012-10-03       Impact factor: 12.015

9.  Involvement of transglutaminase 2 and voltage-gated potassium channels in cystamine vasodilatation in rat mesenteric small arteries.

Authors:  Morten Engholm; Estéfano Pinilla; Susie Mogensen; Vladimir Matchkov; Elise Røge Hedegaard; Hua Chen; Michael J Mulvany; Ulf Simonsen
Journal:  Br J Pharmacol       Date:  2016-01-27       Impact factor: 8.739

10.  A single mutation in helix 8 enhances the angiotensin II type 1a receptor transport and signaling.

Authors:  Shu Zhu; Maoxiang Zhang; Jason E Davis; William H Wu; Kristen Surrao; Hong Wang; Guangyu Wu
Journal:  Cell Signal       Date:  2015-09-02       Impact factor: 4.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.